Skip to main content
Fig. 6 | Molecular Cancer

Fig. 6

From: MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells

Fig. 6

Anti-PD-L1 antibody exhibited in vivo activity on miR155-overexpressing B-cell lymphoma. a PD-L1 antibody treatment significantly abrogated miR155-overexpressing GV369-miR155 tumor growth (right panel), comparing to GV369-CON group (left panel). b Micro-PET/CT showed increased standardized uptake value intensity in miR155-overexpressing GV369-miR155 tumors and the intensity was significantly decreased by anti-PD-L1 antibody treatment. c and d CD8+T cell percentage was induced, as well as CD8+T cell apoptosis and Fas expression were inhibited in GV369-miR155 group treated with anti-PD-L1 antibody. e and f Expression of p-AKT and p-ERK on CD8+T cells was significantly enhanced in GV369-miR155 group treated with anti-PD-L1 antibody

Back to article page

Molecular Cancer

ISSN: 1476-4598